Literature DB >> 27989973

Management of Pyogenic Cerebral Ventriculitis by Neuroendoscopic Surgery.

Fei Wang1, Xiao-Yan Yao1, Zhi-Rong Zou2, Hua-Lin Yu1, Tao Sun3.   

Abstract

BACKGROUND: Pyogenic cerebral ventriculitis is a debilitating form of intracranial infection with an unfavorable outcome as a result of lack of experience in surgical management.
OBJECTIVE: To study retrospectively a group of pyogenic cerebral ventriculitis patients managed by neuroendoscopic surgery (NES).
METHODS: The standard intraventricular protocols of NES to treat this disease included 1 or more of the following: 1) obliteration of debris, 2) evidence of microbial infection, 3) septomy, 4) incision of the septation, or 5) monitoring catheter insertion. Modified external ventricular drainage EVD (mEVD) was combined with NES when intraventricular debris and bacterial plaques could not be evacuated completely. Subsequent surgical treatment strategies depended on the clinical manifestation, cerebrospinal fluid analysis, and mEVD blockage tests approximately 3 weeks after the last NES.
RESULTS: Forty-one patients, who were distributed in 7 hospitals and underwent NES, were included. Five patients received 1 NES, 18 received 2, 16 received 3, and 2 received 4. mEVD was performed in all patients, and mean mEVD duration in the hospital was 27.6 days. At discharge, 15 patients were cured, 15 were cured but ventriculoperitoneal shunt dependent, 9 were mEVD dependent, and 2 died (mean modified Rankin Scale score was 2.48). Two mEVD-dependent patients died, and no other outcomes changed during postoperative follow-up (mean modified Rankin Scale score, 2.67).
CONCLUSIONS: The results suggest a relatively favorable outcome for management of pyogenic cerebral ventriculitis by NES. The techniques and strategies are practical and should be applied more extensively.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neuroendoscopy; Prognosis; Surgery; Ventriculitis

Mesh:

Substances:

Year:  2016        PMID: 27989973     DOI: 10.1016/j.wneu.2016.10.103

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  7 in total

Review 1.  Neuroendoscopic lavage for the treatment of pyogenic ventriculitis in children: personal series and review of the literature.

Authors:  Adalberto Ochoa; Romina Argañaraz; Beatriz Mantese
Journal:  Childs Nerv Syst       Date:  2021-11-13       Impact factor: 1.475

2.  Diagnosis and treatment of severe neurosurgical patients with pyogenic ventriculitis caused by gram-negative bacteria.

Authors:  Feng Shang; Yueqiao Xu; Ning Wang; Weitao Cheng; Wenjin Chen; Wanru Duan
Journal:  Neurol Sci       Date:  2017-10-13       Impact factor: 3.307

3.  Community-Acquired Meningitis Complicated by Pyogenic Ventriculitis: A Case Report.

Authors:  Pabitra Adhikari; Drashti Antala; Bimatshu Pyakuryal; Ahmed Muhammed; Prasun Pudasainee; Harvey Friedman; Chizoba J Ezepue
Journal:  Cureus       Date:  2022-04-07

4.  Pyogenic Ventriculitis and Meningitis Caused by Streptococcus Acidominimus in Humans: A Case Report.

Authors:  Gaurang S Shah
Journal:  Am J Case Rep       Date:  2018-03-22

5.  Application of neuroendoscopic surgical techniques in the assessment and treatment of cerebral ventricular infection.

Authors:  Feng Guan; Wei-Cheng Peng; Hui Huang; Zu-Yuan Ren; Zhen-Yu Wang; Ji-Di Fu; Ying-Bin Li; Feng-Qi Cui; Bin Dai; Guang-Tong Zhu; Zhi-Yong Xiao; Bei-Bei Mao; Zhi-Qiang Hu
Journal:  Neural Regen Res       Date:  2019-12       Impact factor: 5.135

6.  The risk factors of intracranial infection in patients with intracerebral hemorrhage undergone hematoma puncture: what should we care.

Authors:  Haijing Han; Yu Li; Li Liu; Ningning Liu; Ying Wang; Min Zhang
Journal:  BMC Infect Dis       Date:  2020-12-11       Impact factor: 3.090

Review 7.  Current Perspectives on the Diagnosis and Management of Healthcare-Associated Ventriculitis and Meningitis.

Authors:  Marios Karvouniaris; Alexandros Brotis; Konstantinos Tsiakos; Eleni Palli; Despoina Koulenti
Journal:  Infect Drug Resist       Date:  2022-02-28       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.